Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogs

Nucl Med Biol. 2003 Jan;30(1):25-30. doi: 10.1016/s0969-8051(02)00376-1.

Abstract

We have studied the biodistribution of [(18)F]FAU [(1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil], which previous work has shown is incorporated into DNA and functions as an inhibitor of DNA synthesis. It is being tested as a potential antineoplastic agent and imaging agent for PET. We have produced [(18)F]FAU and injected the tracer into 3 normal dogs and imaged them for up to 4 hours and removed tissues along with blood and urine samples for HPLC and activity analysis. The results showed that [(18)F]FAU evenly distributed to most of organs. In sharp contrast to our prior experience with thymidine and its analogs, marrow had less retention of [(18)F]FAU than the non-proliferating tissues.

Publication types

  • Evaluation Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arabinofuranosyluracil / analogs & derivatives*
  • Arabinofuranosyluracil / blood
  • Arabinofuranosyluracil / chemistry
  • Arabinofuranosyluracil / pharmacokinetics*
  • DNA, Neoplasm / metabolism
  • Dogs
  • Fluorine Radioisotopes / blood
  • Fluorine Radioisotopes / chemistry
  • Fluorine Radioisotopes / pharmacokinetics*
  • Organ Specificity
  • Radiopharmaceuticals / blood
  • Radiopharmaceuticals / chemical synthesis
  • Radiopharmaceuticals / pharmacokinetics
  • Tissue Distribution
  • Tomography, Emission-Computed / methods
  • Whole-Body Counting*

Substances

  • 2'-fluorodeoxyuracil-arabinofuranoside
  • DNA, Neoplasm
  • Fluorine Radioisotopes
  • Radiopharmaceuticals
  • Arabinofuranosyluracil